Gentamicin-loaded exosomes from IMMUNEPOTENT CRP enhance healing of infected diabetic wound in mice.

Introduction: Diabetic foot infections (DFIs) are a major cause of lower extremity amputations and are associated with substantial morbidity and reduced quality of life. Given the limited efficacy of current treatments and the rise of antimicrobial resistance, there is an urgent need for innovative therapeutic approaches. This study evaluates the use of exosomes derived from a bovine leukocyte spleen extract (IMMUNEPOTENT CRP), loaded with gentamicin, to improve infection control and promote wound healing in a diabetic setting. Methods: The efficiency of gentamicin encapsulation were evaluated followed by gentamicin release under acidic and alkaline conditions. A wound model was established in streptozotocin (STZ)-induced diabetic mice, followed by inoculation with Results: The Exo-Genta and IMMUNEPOTENT CRP significantly enhanced collagen fiber deposition, blood vessel formation, and hair follicle regeneration. At the molecular level, these treatments increased AKT phosphorylation and modulated the inflammatory response, with reduced levels of TNF-α, IL-6, and MCP-1, alongside a significant increase in anti-inflammatory IL-10. Conclusions: Gentamicin-loaded exosomes derived from IMMUNEPOTENT CRP demonstrated enhanced antimicrobial activity and tissue regeneration in infected diabetic wounds. These findings support their potential as an effective and less invasive therapeutic strategy for diabetic foot ulcers by combining infection control and pro-regenerative and immunomodulatory effects.